TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03181867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL
Description: Subjects will receive IV dose of 18F-DCFPyL by bolus injection. The maximum amount of injected active drug will be less than 4.02 mcg. The target administered activity will be 8 mCi.
Study: NCT03296865

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Kinesio taping
Description: We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.~We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed.
Study: NCT01377428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol
Description: Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
Study: NCT02703831

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single Attending
Description: One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
Study: NCT04208633

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Horizontal placement of the intraocular lens in the capsular bag
Description: The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
Study: NCT01377428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
Study: NCT03181867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG
Description: Cohort 2 may receive a one-time 18F-FDG PET/CT after a positive 18F-DCPyL PET/CT. 18F FDG PET/CT imaging may be performed per clinical standard of care. FDG is administered at a dose of 10mCi intravenously. A whole-body PET/CT will be performed beginning post 18F FDG injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-11
Description: For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA-11
Description: For up to 10 eligible patients from either cohort 1 or 2, an optional salivary gland blocking study may be performed in which a salivary gland is cannulated and injected with unlabeled DCFPyL or PSMA-11.
Study: NCT01160653

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FES-IM
Description: implantable Functional Electrical Stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: training of impaired cognitive processes
Study: NCT04208633

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vertical placement of the intraocular lens in the capsular bag
Description: The eyes will be randomized (1:1) using a dedicated computer programme prior to the start of the study to have a vertical or horizontal placement of the intraocular lens in the capsular bag. The 0 and 180 degrees will be marked on the slit lamp prior to the surgery. The axes of the IOL will be orientated in reference to the midpoint of the optic haptic junction of the IOL. the fellow eye will receive the opposite placement (horizontal or vertical) of the IOL.
Study: NCT03771820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC-6004
Description: NC-6004 should be administered to subjects once every 3 weeks. On Day 1 of each treatment cycle NC-6004 will be administered first followed by pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over 30 minutes every 3 weeks.
Study: NCT03192072

Intervention type: DIAGNOSTIC_TEST
Intervention: Host Gene Expression
Description: comparison to retrospective clinical adjudication
Study: NCT01180114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Suubi-Maka ('Hope for Families')
Description: Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
Study: NCT02824614

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E967-Xylitol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E968-Erythritol
Study: NCT00762060

Intervention type: DEVICE
Intervention: ON-Q Silver soaker System
Description: Continuous infusion of local anesthetic to surgical site
Study: NCT02035982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholinesterase Inhibitor
Description: For participants randomized into the active treatment arm, they will be provided with the following study medications:~Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg~The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
Study: NCT02680886

Intervention type: DEVICE
Intervention: Novosyn® Quick
Description: Skin closure
Study: NCT00413062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DRSP-EE
Description: Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
Study: NCT00278772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: oral, 15mg/kg/day - 30mg/kg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dose, placebo
Study: NCT01244347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folic acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Study: NCT01604876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy 30 min morning and evening, three months
Description: Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.~therapy consists of 30 minutes light exposure in the morning and evening during 3 months.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: light therapy 30 min morning and evening, three months
Description: 200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) \[dimensions 50.2 x 32 x 15.4 cm\] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).~Therapy consists of 30 minutes light exposure in the morning and evening during 3 months.
Study: NCT04694105

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine injection
Description: perineural injection of Bupivacaine 30 ml 0.25% combined with 50 microgram (0.5 ml) peri-neural dexmedetomidine plus 1.5 ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: perineural injection of Bupivacaine 30 ml 0.25% combined with 4 mg peri neural dexamethasone (2 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: perineural injection of Bupivacaine 30 ml 0.25% combined with 2 ml normal saline
Study: NCT02640352

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probi Defendum

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00138424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Description: Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control for this study is sterile, 0.9% normal saline for intravenous use.
Study: NCT02581319

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Periodontal treatment
Description: Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
Study: NCT03801967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977
Description: Randomized participants will receive oral dose of AZD9977.
Study: NCT03528902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Tamoxifen 20 mg po daily for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo
Study: NCT03801967

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomized participants will receive oral dose of matching placebo.
Study: NCT00762060

Intervention type: DRUG
Intervention: Patient controlled analgesia
Description: IV opioids delivered via PCA
Study: NCT00321308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed + PF-3512676
Description: pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
Study: NCT00000371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 50 mg/daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg/day of placebo by mouth
Study: NCT02987348

Intervention type: DRUG
Intervention: exenatide once weekly
Description: patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator

Intervention type: DRUG
Intervention: exenatide twice daily
Description: patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.

Intervention type: DRUG
Intervention: basal insulin
Description: patients with basal insulin treatment under their standard care, no intervention was given by the study investigator

Intervention type: DRUG
Intervention: basal insulin
Description: patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
Study: NCT04058730

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux en Y Gastric by pass surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Management
Study: NCT03515278

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCNB group
Description: IACI can provide rapid effect in pain reliving, reducing inflammation and improving ROM that could increase the compliance of exercise therapy.
Study: NCT02941913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: palonosetron
Description: receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
Study: NCT05585892

Intervention type: OTHER
Group type: OTHER
Intervention: Elaboration and individual mailed feedback
Description: see above

Intervention type: OTHER
Group type: OTHER
Intervention: Elaboration and individual mailed feedback
Description: see above
Study: NCT03515278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IACI group
Description: SCNB is a new choice for treatment of frozen shoulder.As radiology techniques advance, ultrasound-guided SCNB becomes more popular. It provides a cost and time-effective way to infiltrate the nerve accurately without injury to the nerves or vessels.
Study: NCT01996748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF277
Description: Two administrations daily for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two administrations daily for 7 days
Study: NCT03805581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defibrotide
Description: Defibrotide 6.25 mg/kg IV q6h up to 7 days
Study: NCT01667068

Intervention type: OTHER
Intervention: Comprehensive non invasive cardiovascular examination
Description: * Anamnesis with the participian~* File recherche,Physical examination~* Documentation of the carciovascular and antiretroviral medical therapy~* Electrocardiogram~* Transthoracic echocardiography~* Exercise electrocardiogram~* Measuring of the arterial media thickness~* Exercise Montreal Cognitive Assesment test~* Exercise the Grooved Pegboard test~* Blood collection~* Questionnaire to quality of life and health economics
Study: NCT01948388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticotrophin 80 units
Description: Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticotrophin 80 units
Description: Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
Study: NCT00213928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Horse Chestnut Seed Extract
Description: Control (no intervention) vs Horse Chestnut Seed Extract
Study: NCT01149642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Impact
Description: The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.~This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
Study: NCT02034474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8mg/kg intravenously via iv drip over 60 min
Study: NCT03912168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Question Prompt List
Description: Question prompt list for common orthopaedic conditions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3 questions list
Description: 3 questions from the AskShareKnow model
Study: NCT02034474

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously via iv drip over 60 min
Study: NCT01432262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine-13vPnC
Description: Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine-13vPnC
Description: Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
Study: NCT01953328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally once a day
Study: NCT03621826

Intervention type: OTHER
Intervention: Questionnaire/Interview
Description: A convenience sample of patients/parents and stakeholders will be asked to participate in a survey and/or interview to evaluate barriers to care in sickle cell.
Study: NCT01953328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally once a day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study: NCT01763918

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT05260086

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuronavigated aiTBS
Description: Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronavigated aiTBS
Description: Accelerated intermittent theta burst stimulation (aiTBS, 4 sessions per day with at least 20 minutes pause between sessions) in the left dorsolateral prefrontal cortex (DLPFC)
Study: NCT01060514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: dose escalation, administered orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
Study: NCT02722070

Intervention type: DEVICE
Intervention: 3 Tesla Siemens Skyra MRI scanner
Description: Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging

Intervention type: DEVICE
Intervention: 3 Tesla Siemens Skyra MRI scanner
Description: Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging

Intervention type: DEVICE
Intervention: 3 Tesla Siemens Skyra MRI scanner
Description: Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging

Intervention type: DEVICE
Intervention: 3 Tesla Siemens Skyra MRI scanner
Description: Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
Study: NCT02807467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
Study: NCT01318382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOF-Watch SX® Monitoring of NMB
Description: Participants will have the extent of NMB monitored by a TOF-Watch SX®.